Novel non-reverting salmonella live vaccines
AssigneeThe Board of Trustees of the Leland Stanford Jr. University
InventorBruce A. D. Stocker
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Board of Trustees of the Leland Stanford Jr. University
InventorBruce A. D. Stocker
Estimating the term…
Live vaccines are provided and methods for preparing the live vaccines for protection of a host from a pathogenic microorganism. The vaccines are prepared by introducing at least one modification in a gene involved in at least one, normally at least two, biosynthetic pathways, involving the production of products which are unlikely to be found in the disease susceptible host. The modification results in a gene change which cannot be repaired by a single step e.g. polynucleotide deletions and inversions. Where the aro gene suffers such a change, the resultant auxotrophic mutants require aromatic amino acids, p-aminobenzoic acid and 2,3-dihydroxybenzoic acid or a highly concentrated source of absorbable iron. The auxotrophic mutations have substantially reduced or nonexistent virulence, while retaining the desired immunogenicity to initiate the immunogenic response. Various techniques can be employed for providing the desired change. Salmonella typhimurium strain SL1479 was deposited at the ATCC on Sept. 7, 1982 and given ATCC Accession No. 39183; Salmonella dublin strain SL1438 was deposited on Sept. 7, 1982 at the ATCC and given ATCC Accession No. 39184. Salmonella typhi strain 531Ty was deposited at the ATCC on Nov. 21, 1984, and granted ATCC Accession No. 39926.
A method for preparing a live attentuated vaccine from a virulent pathogenic bacterial microorganism, which vaccine has substantially zero probability of reverting to virulence in a vertebrate host, said method comprising:
A method of preparing a live attenuated vaccine from a virulent pathogenic bacterium, which vaccine has a substantially zero probability of reverting to virulence in a vertebrate host, said method comprising:
A method for preparing a live non-virulent vaccine from a virulent pathogenic bacterium having substantially unaltered O antigenic character, which vaccine has a substantially zero probability of reverting to virulence in a vertebrate host susceptible to said bacterium, said method comprising:
Dependencies are inferred from the claim text.